Welcome to our dedicated page for I-Mab SEC filings (Ticker: IMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NovaBridge Biosciences, formerly I-MAB, files foreign private issuer current reports that document its corporate transition, ADS structure, governance, material agreements and precision immuno-oncology disclosures. Its Form 6-K reports record the shareholder-approved name change from I-MAB to NovaBridge Biosciences, the amended memorandum and articles of association, and the commencement of Nasdaq trading under the NBP ticker for the company's ADSs.
The filings also describe capital-structure and registration-statement incorporation matters, director and board committee changes, the completed Bridge Health acquisition and related CLDN18.2 antibody rights, subsidiary license and assignment arrangements, and clinical exhibits for givastomig in Claudin 18.2-positive gastroesophageal carcinoma.
I-MAB has announced positive Phase 1b dose escalation data for their drug candidate Givastomig in combination with immunochemotherapy for first-line treatment of gastric cancers. The results were presented at the ESMO GI 2025 conference.
This Form 6-K, filed by the Maryland-based biopharmaceutical company, includes an exhibit (99.1) containing the press release detailing the clinical trial outcomes. The filing was signed by Joseph Skelton, the company's Chief Financial Officer.
The filing indicates that I-MAB continues to file annual reports under Form 20-F as a foreign private issuer. This development represents a significant milestone in I-MAB's oncology pipeline, particularly in the gastric cancer treatment landscape.